Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular and Biliary Tract
Neuroendocrine | PancreaticOpening Soon | All Cancer Trials at UCSF

 

COLORECTAL

METASTATIC
 
CC# 12451: A phase III clinical trial evaluating TheraSphere® in patients with metastatic colorectal carcinoma to the liver who have failed first line chemotherapy (TS-102)
Contact: Curt Johanson (415) 353-2310: curt.johanson@ucsf.edu
 
CC# 124522 (Novartis# MEK116833): An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E or V600K Positive Colorectal Cancer
Contact: Marissa Savoie (415) 353-7683: Marissa.Savoie@ucsf.edu
 
CC# 154518: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)
Contact: Claire Greene (415) 514-6258: claire.greene@ucsf.edu
 
CC# 159510A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer
Contact: Armand Harb (415) 353-7381: Armand.Harb@ucsf.edu
 
NEOADJUVANT RECTAL

Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu
 
ANAL

CC# 159522A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158)
Contact: Wesley Goodman-Levy (415) 514-6363: Wesley.Goodman-Levy@ucsf.edu

 

EARLY PHASE

 
CC#13954A Phase 1 Study to Evaluate the Effect of NKTR-102 for Injection (etirinotecan pegol) on the QT/QTc Interval in Patients with Advanced or Metastatic Solid Tumors
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 
CC#13955An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment 
Contact: Jeremy Burbanks-Ivey (415) 514-6248: Jeremy.Burbanks-Ivey@ucsf.edu
 
CC#14951: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors
Contact: Armand Harb (415) 353-7381: Armand.Harb@ucsf.edu
 
CC#149511: A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 
CC#149515Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects with Advanced/Relapsed Solid Tumors
Contact: Jeremy Burbanks-Ivey (415-514-6248): Jeremy.Burbanks-Ivey@ucsf.edu
 
CC#149517Phase I study to evaluate the safety of Neratinib in combination with Paclitaxel, Trastuzumab and Pertuzumab in women and men with advanced or metastatic HER2+ solid tumors
Contact: Wesley Goodman-Levy (415-514-6363): Wesley Goodman-Levy@ucsf.edu
 
CC#15955: A Multi-Center Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors
Contact: Jeremy Burbanks-Ivey (415-514-6248): Jeremy.Burbanks-Ivey@ucsf.edu
 
CC#15956A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers
Contact: Khanh Cao (415) 3553-7084: Khanh.Cao@ucsf.edu
 
CC# 15957A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors
Contact: Jim Leng (415) 443-1588: Jim.Leng@ucsf.edu
 
CC# 159510A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer
Contact: Armand Harb (415-353-7381) Armand.Harb@ucsf.edu
 
CC# 159512A Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Is Available
Contact: Kathleen (Kate) Comerford (415-514-6674): Kathleen.Comerford@ucsf.edu
 
CC# 159518A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 
CC# 159522A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158)
Contact: Wesley Goodman-Levy (415) 514-6363: Wesley.Goodman-Levy@ucsf.edu
 

GASTRO ESOPHAGEAL

CC#154515A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors
ContactSamantha Maisel (415) 476-5442: Samantha.Maisel@ucsf.edu
 
CC#154525A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
ContactClaire Green (415) 514-6258: Claire.Greene@ucsf.edu
 

HEPATOCELLULAR AND BILIARY TRACT

 
CC# 13455: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Contact: Blake Rosenthal (415)514-5633; Blake.Rosenthal@ucsf.edu

CC# 11452: Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib
Contact: McKinley Nickerson (415)514-6314: NickersonM@cc.ucsf.edu
CC# 154514: A Phase II Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC)
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu
CC# 159522A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158)
Contact: Wesley Goodman-Levy (415) 514-6363: Wesley.Goodman-Levy@ucsf.edu
CC# 154523A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma
Contact: Anna Crosetti (415) 514-8101: Anna.Crosetti@ucsf.edu
CC# 16451A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremeliumumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Contact: Andrea Bocobo (415) 476-3755: Andrea.Bocobo@ucsf.edu

NEUROENDOCRINE TUMORS

 
EA2142: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Contact: Hannah Mills (415) 353-7792: Hannah.Mills@ucsf.edu
 
CC#14453: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Contact: Thomas Hope: Thomas.Hope@ucsf.edu
 
CC#149511A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 
CC#159522A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158)
Contact: Wesley Goodman-Levy (415) 514-6363: Wesley.Goodman-Levy@ucsf.edu

 

PANCREATIC

CC#14455: A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer
Contact: Hannah Mills (415)514-6258: Hannah.Mills@ucsf.edu

CC#144515: A Phase I Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Borderline Resectable Pancreatic Cancer
Contact: Daniela Rodriguez-Jaquez (415)353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu

CC#144525: A Phase Ib/II Safety and Efficacy Trial of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Contact: Hannah Mills (415) 514-6258: Hannah.Mills@ucsf.edu

CC#15454A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma
Contact: Marissa Savoie (415) 353-7683: Marissa.Savoie@ucsf.edu

CC#15459A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of MM-141 plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu

CC#15955A Multi-Center Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors
Contact: Jeremy Burbanks-Ivey (415-514-6248): Jeremy.Burbanks-Ivey@ucsf.edu

CC#15957: A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors
Contact: Jim Leng (415) 443-1588: Jim.Leng@ucsf.edu

**************************************************
 

**TO BE OPENED WITHIN 3 MONTHS**

CC159513: A Phase 1b Study of AZD1775 (WEE1 inhibitor) Monotherapy in Patients with Advanced Solid Tumors
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC154524: A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers
Contact: Emily Mitchell (415) 476-5442 Emily.Mitchell@ucsf.edu

AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC# 15958: Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC# 159516: A phase Ib, open-label study of alpelisib (BYL719) in combination with cisplatin in patients with HPV+ solid tumor malignancies
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC# 159515: A Phase IB, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC# 159523: A Phase 1/2a study to assess the safety, PKs & PDs of PLX8394 in Patients with Advanced, Unresectable Solid Tumors
Contact: Ilaria Mastroserio (415) 514-6245 Ilaria.Mastroserio@ucsf.edu

CC #16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Contact: Curt Johanson (415)353-2310: Curt.Johanson

CC#16456: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma who Progressed on or Were Intolerant to First-Line Systemic Therapy
Contact: Claire Greene (415) 514-6258: Claire.Greene@ucsf.edu

CC#16457: Protocol I3O-MC-JSBF Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
Contact: Claire Greene (415) 514-6258: Claire.Greene@ucsf.edu

 

For information on Phase 1 clinical trials not listed in this newsletter please contact:
Anne Reinert, NP (415) 415-353-9291: Anne.Reinert@ucsfmedctr.org